Sarju Ganatra to Cardiotoxicity
This is a "connection" page, showing publications Sarju Ganatra has written about Cardiotoxicity.
Connection Strength
2.051
-
Malode A, Makwana B, Patel V, Khadke S, Parikh A, Bagga A, Dani S, Ganatra S. Cardiotoxicity and peri-operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T-cell therapy: a narrative review. Anaesthesia. 2025 Feb; 80 Suppl 2:25-37.
Score: 0.937
-
Makwana B, Malode A, Khadke S, Patel V, Shah R, Patel M, Parikh A, Dani SS, Ganatra S. Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor?T Cell Therapy. Cardiol Clin. 2025 Feb; 43(1):151-167.
Score: 0.228
-
Titus A, Cheema HA, Shafiee A, Seighali N, Shahid A, Bhanushali KB, Kumar A, Khan SU, Khadke S, Thavendiranathan P, Hundley WG, Scherrer-Crosbie M, Nohria A, Neilan TG, Dani SS, Nasir K, Ganatra S. Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis. Curr Probl Cardiol. 2023 Oct; 48(10):101885.
Score: 0.210
-
Patel RP, Parikh R, Gunturu KS, Tariq RZ, Dani SS, Ganatra S, Nohria A. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep. 2021 05 03; 23(7):79.
Score: 0.181
-
Suero-Abreu GA, Ganatra S, Neilan TG. Cardiotoxicity Monitoring in Patients With Cancer: Focus on Safety and Clinical Relevance. JCO Oncol Pract. 2021 05; 17(5):237-239.
Score: 0.180
-
Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of Immune Therapy. Cardiol Clin. 2019 Nov; 37(4):385-397.
Score: 0.161
-
Palaskas NL, Ali HJ, Koutroumpakis E, Ganatra S, Deswal A. Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024 05 15; 385:e075859.
Score: 0.056
-
Stein-Merlob AF, Ganatra S, Yang EH. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies. Heart Fail Clin. 2022 Jul; 18(3):443-454.
Score: 0.049
-
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
Score: 0.047